drugset / Trial / NCT05945147

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

NCT05945147

Phase 2 Withdrawn Stanford University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).

Timeline

Start
2099-01-01
Primary completion
2099-04-30
Completion
2099-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.4 mg/kg Intravenous
Subject Midazolam Small molecule 0.04 mg/kg Intravenous